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INTRODUCTION 
Diltiazem is a calcium ion influx inhibitor (calcium entry 
blocker or calcium ion antagonist). The antihypertensive, 
antianginal and antiarrhythmic effects of diltiazem is 
believed to be related to its specific cellular action of 
selectively inhibiting transmembrane influx of calcium in 
cardiac muscle, coronary arteries, and systemic arteries and 
in cells of the intracardiac conduction system1. Given orally, 
90–100% of diltiazem is absorbed, but due to high first pass 
metabolism, bioavailability is much lower (40–60%), half 
life is 6–9 hours (with chronic dosages) and not cleared by 
hemodialysis2-3. 
Solid lipid microparticles (SLMs) were developed in early 
1990s and have since been considered to be promising drug 
carrier systems4, especially with a view to give the 
incorporated active substance a sustained release profile5-6. 
These are monolithic spherical structures with the drug 
distributed through out the microsphere matrix either as a 
molecular dispersion or as particle dispersion7.  Solid lipids 
are advantageous pharmaceutical excipients being low cost, 
natural and biodegradable products with physiological, non 
toxic properties8-9. The drug solubility and miscibility in 
melted lipid10, chemical and physical structure of lipid 
materials, and their polymorphic state determine the loading 
capacity of drug in the lipid particles11-12.  
 
Furthermore, the use of synthetic polymer matrix materials 
often goes along with detrimental effects on incorporated 
peptides during manufacturing of the formulations or during 
the erosion of the polymers after application13-14. Lipid 
materials, e.g. triglycerides and cholesterol15, may have the 
potential as biocompatible and biodegradable carriers for 
peptides and proteins16-17. In our study, we investigated the 
potential of physiological lipids such as monoglyceride as 
well as an alternative to polymers as a matrix material for 
controlled release devices for the diltiazem hydrochloride18-
19. The aim of this study was to investigate various methods 
of preparing lipid microparticles with respect to their 
suitability to encapsulate diltiazem hydrochloride20-21 and to 
characterize the resulting systems with respect to particle 
size 22, modification of the lipid matrix and the in-vitro 
release behavior5. 
MATERIALS AND METHODS 
Materials 
Diltiazem hydrochloride was received from Vipro 
Lifescience, (Gujarat, India), SOFTEMUL® - AS (glycerol 
monostearate), poly (vinyl alcohol), diethyl ether, span 60 
grade from Pure Chemicals Co (Chennai, Tamil Nadu). 
 
ABSTRACT:  
Diltiazem, a benzodiazepine, voltage sensitive ca2+ channel blocker with a high therapeutic potential but with a very 
short biological half life was encapsulated within microparticles. The encapsulation efficiency of prepared SLM 
reached 70.48±1.67% w/w. Further, the particle size (99.52±1.06μm), surface morphology (spherical) and drug 
loading efficiency (17.62±2.14%w/w) were investigated. Various formulation and process parameters like drug 
polymer ratio (3:1), nature and concentration of emulsion stabilizer in the external aqueous i.e. aqueous PVA solution 
(0.1%), phase viscosity of external aqueous phase (0.5%), volume of external aqueous phase and stirring rate (1000 
rpm for 2 h) were optimized. The in-vitro release of diltiazem from the microparticles as observed with the initial 
burst release of 17% followed by the slow release to avoid dose dumping. The analytical methodology employed for 
characterization included UV and IR Spectroscopy, DSC, physicochemical stability studies which proves that the 
prepared solid lipid microparticles appear to have promising abilities for oral administration of diltiazem 
hydrochloride with improved half life, improved bioavailability and minimized local and systemic GI disturbances. 
Keywords: Benzodiazepine, solvent evaporation method, biodegradable polymer, sustained release, encapsulation 
efficiency. 
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Preparation methods of lipid microparticles 
Solvent evaporation method widely used for the preparation 
of polymeric microparticles. In this method drug and 
polymer were dissolved in organic solvent, this mixture was 
kept on a magnetic stirrer. Aqueous solution of 0.5% w/v of 
polyvinyl alcohol containing Span 60 (0.1% w/v) as an 
emulsifier were stirred with the help of mechanical stirrer. 
Then, both the mixtures were added and stirred at 1000 rpm. 
Microparticles were filtered, washed with acetone and 
vacuum dried over night at room temperature. 
Scanning electron microscopic 
The surface topography of microparticles prepared by 
different methods was analyzed by scanning electron 
microscopy. The prepared microparticles were coated with 
gold palladium under an air atmosphere for 150 seconds to 
achieve a 20nm film (Coater Polaron,18mA current at 1.4 
kV).The coated sample were then examined using SEM 
(Philips 505, Philips, Holland).   
Particle size distribution 
 A laser light scattering technique (Mastersizer, Malvern 
Instruments, UK) was employed to confirm the particle size 
distribution of solid lipid microparticles. The dried powder 
samples were suspended in deionised water and sonicated 
for 1 min with an ultrasound probe before measurement. 
The compressed air system was utilized to inhibit the 
aggregation of dried microparticles23. 
Differential scanning calorimetry (DSC) 
Differential Scanning Calorimetry studies of Diltiazem and 
glycerol monostearate was carried out by heating the 
samples from 40oC to 240oC at the rate of 20oC/min, using 
UNIVERSAL Q 200 V 23.5 instrument24.  
In-vitro release study 
In-vitro dissolution studies were carried out on the 
microparticles at the temperature of 37oC±0.5oC and at 100 
rpm using USP Dissolution Apparatus II. Initially the 
dissolution studies were performed in simulated gastric fluid 
consisting of 0.1N (pH 1.2) hydrochloric acid without 
enzyme. An accurately weighed sample of microparticles 
was suspended in the media and dissolution study was 
carried out for 2 hr. At the end of the 2 hr, 400 ml of 0.1M 
tribasic sodium phosphate, pH was adjusted to 7.2±0.2 and 
added to all 6 dissolution vessels. The dissolution was 
continued until the microparticles were depleted of drug25-26. 
In-vivo release study 
The oral pharmacokinetic study of diltiazem hydrochloride 
SLM intended for the sustained release delivery, was carried 
out in albino rats, which were divided in two groups each 
with six animals of weight 250-300 grams. The animals 
were fasted for 24 hr following the oral administration of 0.5 
ml suspension of diltiazem hydrochloride SLM in distilled 
water. The plasma samples were withdrawn from retro 
orbital plexus region of rats at time intervals of 0, 1, 2, 4, 8, 
12 and 24 hr of post administration, in the animals lightly 
anesthetized with ether.  
Analysis of diltiazem hydrochloride from rat plasma 
The plasma samples withdrawn at 0, 1, 2, 4, 8, 12 and 24 h 
time interval were deproteinised using acetonitrile, subjected 
to centrifuge at 10,000 rpm for 10 minutes at the temp of -
4oC. The clear supernatant was separated through 
micropipette and the drug content was analyzed using 
HPLC.  
Pharmacokinetic parameters of diltiazem hydrochloride 
SLM 
Oral Pharmacokinetic parameters such as maximum plasma 
concentration (Cmax), time to reach maximum 
concentration (Tmax), half life (T1/2), mean residence time 
(MRT), were calculated using graph pad Version 5.0 
software. 
Stability study 
Prepared formulation was stored in screw capped small 
glass bottles at 4±1°C, 60±5% RH and 25±1°C, 65±5% RH. 
Samples were analyzed for residual drug content after a 
period of 15, 30, 45, 60 and 90 days. Initial drug content 
was taken as 100 % for each formulation. The log percent 
residual drug content was plotted against time (t), which 
reflected an almost linear relationship. 
Statistical analysis 
Determination of corrected drug concentration: the corrected 
drug concentration at each time interval was calculated 
using the formula given below: 
1n
1i
uctsucc C/VVCC  
1n
1i
ucC  = Sum of previous uncorrected drug concentration. 
Cc = Corrected drug concentration. 
Cuc = Uncorrected drug concentration. 
Vs = Volume of sample withdrawn. 
Vt = Total volume of dissolution medium. 
RESULTS AND DISCUSSION 
The method employed for the preparation of drug loaded 
biodegradable microparticles is the solvent evaporation 
technique. The present study investigated that diltiazem 
containing lipid microparticles can be produced in the 
preferred size range as a substitute to polymeric 
microparticles.  
Selection of optimum Polymer: drug ratio 
Diltiazem hydrochloride loaded microparticles were 
prepared using different polymer: drug ratio. Increasing the 
weight of polymer in a fixed volume of organic solvent 
resulted in an increase in mean particle size (from 71.43 ± 
2.38μm to 113.52 ± 2.85μm for 1:1 to 5:1) as shown in Fig. 
1 and Table 1.
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Figure 1: Effect of polymer: drug ratio on average particle size and percent drug entrapment 
Table 1 Effect of polymer: drug ratio on microparticles characteristics 
Batch 
Code 
Polymer: drug 
ratio (w/w) 
Mean diameter (μm) 
Drug Loading (%, 
w/w) 
Entrapment efficiency 
(%, w/w) 
Process yield 
(%w/w) 
DT-1 1:1 71.43 ± 2.38 22.74 ± 1.46 42.48 ± 2.46 62.08 ± 1.34 
DT -2 2:1 85.83 ± 1.47 19.75 ± 1.46 57.26 ± 1.45 64.46 ± 2.47 
DT -3 3:1 98.52 ± 1.37 16.62 ± 2.56 71.48 ± 1.66 87.43 ± 1.45 
DT -4 4:1 106.44 ± 1.47 13.98 ± 1.89 60.92 ± 2.56 63.53 ± 1.54 
DT -5 5:1 113.52 ± 2.85 11.48 ± 2.45 61.87 ± 1.64 62.67 ± 1.65 
 
 
Figure 2: Effect of emulsifier concentration on average particle size and percent drug entrapment 
Table 2 Effect of emulsifier concentration on microparticles characteristics 
Batch 
Code 
Emulsifier conc. 
(%w/w) 
Mean diameter 
(μm) 
Drug Loading 
(%w/w) 
Entrapment efficiency 
(%, w/w) 
Process yield 
(%w/w) 
DT-3 0.05 110.98±1.34 18.98±2.37 71.94±1.82 62.30±1.83 
DT -3 0.1 101.64±1.56 19.37±1.04 72.48±1.01 84.30±2.11 
DT -3 0.2 93.54±1.84 18.16±1.98 69.66±0.96 65.80±1.58 
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Nature and concentration of emulsion stabilizer in the 
external aqueous phase 
Among the entire stabilizer studied, span 60 resulted in 
successful preparation of microparticles. Finally, 0.1%w/v 
span 60 was selected as a stabilizer of choice, since it 
allowed the preparation of particles in the size range of 
101.64±1.56 μm with a considerable higher drug loading 
about 19.37±1.04 (w/w) in Fig. 2 and table 2.  
Selection of optimum aqueous: oil phase ratio 
As external dispersing phase different volumes of PVA 
aqueous solution were employed, resulting in different ratios 
between aqueous as external and oil as internal phases. 
Particles produced by  20:1 w/o ratio (200 ml) enabled the 
production of spherical microparticles with a mean diameter 
of 101.37 ± 2.14 μm, having the process yield of 83.24 ± 
1.47% (w/w), the encapsulation efficiency of 75.13 ± 1.98% 
(w/w) and drug loading of 17.23 ± 1.38% (w/w). Table 3 
and Fig. 3 summarizes the obtained results.
 
 
Figure 3: Effect of aqueous: oil phase ratio on average particle size and percent drug entrapment. 
Table 3 Effect of aqueous:oil phase ratio on microparticles characteristics 
Batch 
Code 
Aqueous:oil 
phase ratio 
Mean diameter (μm) 
Drug Loading 
(%w/w) 
Entrapment efficiency 
(%, w/w) 
Process yield 
(%w/w) 
DT-3 15:1 109.74±2.67 16.58±1.54 67.42±2.45 65.24±2.15 
DT -3 20:1 101.37±2.14 18.23±1.38 74.13±1.85 84.24±1.67 
DT -3 30:1 92.28± 1.18 17.56±2.13 70.39±2.37 67.54±1.88 
 
Optimum viscosity of the external aqueous phase 
Increasing viscosity of the external phase by addition of the 
increasing concentration of PVA led to a slight increase in 
the particle size 93.53±1.4 μm with 0.1% PVA to 
138.85±0.89 μm with 1.0% PVA. The use of 0.5% PVA led 
to the formation of spherical particles with a mean diameter 
of 101.47±1.73 μm with the process yield of 84.34±0.64% 
(w/w), drug loading of 18.46±1.25% (w/w) and an 
encapsulation efficiency of 72.82±1.34% (w/w) which was 
highest among all the three concentrations of PVA (Fig. 4 
and Table 4).  
Table 4 Effect of viscosity of aqueous phase on microparticles characteristics 
Batch 
Code 
Viscosity 
(% w/v) 
Mean diameter 
(μm) 
Drug Loading 
(%w/w) 
Entrapment efficiency (%, 
w/w) 
Process yield 
(%w/w) 
DT-3 0.1 93.53±1.4 17.83±2.18 71.47±1.45 64.34±2.55 
DT -3 0.5 101.47±1.73 18.46±1.25 72.82±1.34 84.34±0.64 
DT -3 1.0 138.85±0.89 17.19±1.98 70.75±2.09 65.34±2.56 
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Figure 4: Effect of viscosity of aqueous phase on average particle size and percent drug entrapment 
Optimum stirring speed 
Stirring speed plays an important role in the microparticles 
size distribution and drug loading. On increasing the stirring 
speed up to 1500 rpm spherical microspheres were obtained. 
The microspheres at such high shear rate possessed 79.52 ± 
1.32 μm mean diameter, 64.54 ±2.17% (w/w) process yield, 
drug loading 16.31 ± 0.16% (w/w) and 62.94 ± 3.43% (w/w) 
encapsulation efficiency [28]. The best results in term of 
process yield were obtained by the use of 1000 rpm stirring 
speed (84.33 ± 1.22%, w/w), microparticles in this condition 
were spherical, with 98.26 ± 1.53 μm mean diameter, drug 
loading 19.53 ± 2.04% (w/w) and 74.61 ± 1.34% (w/w) 
encapsulation efficiency. Table 5 summarizes the 
comparison of obtained results (Fig. 5)
 
 
Figure 5: Effect of stirring speed on average particle size and percent drug entrapment 
Table 5 Effect of stirring speed on microparticles characteristics 
Batch 
Code 
Stirring speed 
(rpm) 
Mean diameter (μm) Drug Loading 
(%w/w) 
Entrapment efficiency 
(% w/w) 
Process yield 
(%w/w) 
DT-3 500 109.43±1.34 17.18±1.45 65.71±1.85 63.34±1.08 
DT -3 1000 98.26 ± 1.53 19.53 ± 2.56 74.61 ± 1.34 84.33 ± 1.22% 
DT -3 1500 83.45±1.92 14.61±1.54 57.44±2.13 62.34±2.37 
 
Optimum stirring time 
For a constant speed of 1000 rpm, a polymer:drug ratio of 
3:1, a w/o ratio of 20:1 and a 0.5% viscosity of aqueous 
phase, an increase of the stirring time from 1 to 3 h  
 
resulted in reduction in microparticles size (from 115.68 ± 
2.43 to 81.66 ± 2.68 μm). A 2 h stirring time was chosen 
because the entrapment efficiency was higher (76.08 ± 
1.62%, w/w) than after 2 h (69.92 ± 1.23%, w/w) (Fig. 6).  
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Figure 6: Effect of stirring time on average particle size and percent drug entrapment 
 
Figure 7: SEM photographs of microparticles: a) Diltiazem loaded group of particles and b) Diltiazem loaded single particle 
Scanning electron microscopic studies 
The spherical shape of microparticles was established by 
SEM. The surface analysis of empty and of drug loaded 
microparticles prepared by the w/o/w emulsion solvent 
evaporation method revealed that the microparticles were 
spherical with a diameter of 101.75 ± 0.82 μm and 
polydispersity index of as shown in Fig. 7 
Differential scanning calorimetric studies 
In the drug loaded microparticles of glycerol monostearate, 
thermogram showed a peak at 63.75oC corresponding to the 
melting point of glycerol monostearate. This shift may be 
due to physicochemical interaction of drug and polymer as 
shown in fig. 8. 
 
Figure 8: DSC thermogram of pure drug (Diltiazem Hydrochloride) and lipid 
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Size distribution and Size statistics 
The measurement achieved by laser light scattering in order 
to estimate the average diameter of solid lipid microparticle 
of diltiazem hydrochloride evidenced the presence of some 
aggregates with average diameter 105.71µm, and particle 
size ranged between 95.76 to 115.38 µm thus presenting 
unimodal and narrow particle size distribution as shown in 
Fig. 9. 
In-vitro release studies 
In-vitro Diltiazem Hydrochloride release studies from 
glycerol monostearate microparticles were performed for 2 h 
in pH 1.2 buffer (Simulated gastric fluid) and after 2 h in 
phosphate buffer, pH 7.2 (Simulated intestinal fluid) at 
temperature of 37 ± 0.5oC. Diltiazem release from the 
microparticles was found to be slow and spread over 
extended period of 24 h28 as shown in Fig. 10. Percent of 
Diltiazem released from the microparticles was decreased 
with an increase in amount of coat material in the 
microparticle formulation (p<0.05). The increased density of 
the polymer matrix at higher concentrations results in an 
increased diffusional pathlength26. This may decrease the 
overall drug release from the polymer matrix. Furthermore, 
smaller microparticles are formed at a lower polymer 
concentration and have a large surface area exposed to 
dissolution medium, giving rise to faster drug release10-27.  
Initial release stage 
About 17% rapid drug release was noticed just a few 
minutes after suspending the microparticles in the acid 
solution medium and higher release rates were associated 
with smaller size fraction. Under the microscope, drug 
crystal could be observed at or near the surface of the 
microparticles. These surface crystals would dissolve 
quickly and probably account for the rapid initial release27. 
 
 
Figure 9: Size distribution and Size statistics report by intensity 
 
 
Figure 10: In-Vitro release curves of microparticles 
Release in acid after initial stage 
Most of the drug release during this time period is mainly 
due to the initial release and could be removed with an acid 
wash prior to the dissolution analysis27. Diltiazem release 
from microparticles was negligible during this stage. 
Release at pH 7.2 
During the dissolution in the slightly neutral buffered 
medium pH 7.2, higher release rates were noticed for the 
microparticles as a result of the creation of pores and 
channels and probably due to swelling of polymers to some 
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extent. It is evident that slopes are larger in the slightly 
neutral medium than in acidic one. 
Kinetics of drug release 
In order to investigate the release mechanism of present 
drug delivery system, the data obtained from in-vitro release 
of final optimized batch (DT-03) were fitted into equations 
for the zero-order, first-order, Higuchi release model and 
Krosmeyer Peppas model. The interpretation of data was 
based on the values of the resulting regression coefficients. 
The in-vitro drug release showed the regression coefficient 
values for Higuchi’s model (r2 = 0.9759) and Krosmeyer 
Peppas model (r2 = 0.986) and a value of n = 0.576 
represented in Fig. 11 and 12 respectively, indicating 
anomalous transport29 
. 
 
Figure 11: Korsmeyer Peppas plot of the optimized batch (DT-03) 
 
Figure 12: Higuchi’s plot of the optimized batch (DT-03) 
In-vivo studies 
In-vivo studies were carried out in albino rats as per the 
established protocol and the pharmacokinetic parameters 
were determined. 
Pharmacokinetic parameter of SLM 
Pharmacokinetic analysis was carried out to determine oral 
parameters using comparative results from drug aqueous 
suspension and SLM of the diltiazem hydrochloride 
administered to II and III group respectively. Significantly 
higher Cmax values were observed for SLM formulation 
compared to aqueous oral suspension of same drug as shown 
in Fig. 13. The highest concentration value achieved in case  
 
of drug suspension was 218.59±1.47 and the Cmax value for 
SLM formulation was observed as 235.85±1.29. Tmax value 
remained for 8 h (i.e., between 4h to 12 h time interval) in 
the SLM formulation indicating sustained release of drug 
whereas in pure drug without polymer, the highest 
concentration (Cmax) was observed at first time point, i.e.,  
2 h, this was considered as Tmax. MRT of diltiazem SLM 
formulation was considerably higher than the drug 
suspension. Half life of drug increased many fold and was 
found to be 12 h in SLM formulation and 2 h in drug 
suspension of diltiazem hydrochloride as shown in Table 8.
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Figure 13: In-vivo release study of SLM and pure drug without polymer 
Table 8 Pharmacokinetic parameters following the oral administration of diltiazem-loaded SLMs to albino rats, as compared 
to oral free drugs 
Parameters Control SLM Drug suspension 
Cmax 0 235.85±1.29 218.59±1.47 
Tmax 0 4±2.10 2±3.29 
Cmax, maximum concentration; Tmax, maximum time to reach Cmax concentration 
Mean ± S.D. (Standard deviation), n=3 
Stability studies 
Diltiazem Hydrochloride microparticles in the form of 
lyophilized powder were stored in glass bottles at 4 ± 1oC, 
60 ± 5 % RH and 25 ± 1oC, 75  ± 5% RH for period of 3 
months and evaluated for any change in the shape and 
structural integrity by microscopic examination and residual 
drug content. At 25 ± 1oC, agglomerates of microparticles 
were found after storage for three months, which may be 
attributed to polymer softening and fusion. Optimal storage 
conditions for the formulation assessed by analyzing the 
residual drug content after the time interval of 15, 30, 45, 60 
and 90 days. The percent residual drug content was 
determined and found to be 99.11±0.59 at 4 ± 1oC (Table 9) 
and 98.28±0.98 at 25 ± 1oC (Table 10) respectively after 
storage for 90 days. (Fig. 14 and 15) Microparticles 
formulation stored at 4 ± 1°C showed the k value as 11.51 × 
10-4, t10% value of nearly 94.45 days, t1/2 value was 602.61 
days, while those stored at 25 ± 1oC showed the k value as × 
10-4 and t10% value of nearly 45.1 days, t1/2 value of nearly 
301.30 days. 
The log % residual drug content vs. time graph was plotted 
for the optimized formulation in order to evaluate k (specific 
rate constant or degradation rate constant), t1/2 and t10% of 
the formulation.  
 
Table 9 Effect of aging on residual drug content at 4 ± 1°C 
Formulation 
% Residual Drug Content (at 4 ± 1˚C.) 
Mean ± S.D., n=3 
0 Days 15 Days 30 Days 45 Days 60 days 90 Days 
DT-3 100 99.57±0.36 99.41±0.20 99.28±0.38 99.19±0.64 99.11±0.59 
Log % of drug 
remaining 2 1.998 1.997 1.996 1.996 1.996 
 
 
 
Pilaniya et al                             Journal of Drug Delivery & Therapeutics; 2011, 1(1): 48-59            57 
© 2011, JDDT. All Rights Reserved 
 
Table 10 Effect of aging on residual drug content at room temperature 
Formulation 
% Residual Drug Content ( at 25 ± 1oC) 
Mean ± S.D., n=3 
0 Days 15 Days 30 Days 45 Days 60 days 90 Days 
DT-3 100 99.12±0.48 98.98±0.29 98.67±1.29 98.48±1.38 98.28±0.98 
Log % of drug 
remaining 2 1.996 1.995 1.994 1.993 1.992 
 
 
Figure 14: Effect of aging on log % residual drug content at 4 ± 1°C 
 
Figure 15: Effect of aging on % residual drug content at 25 ± 1°C 
CONCLUSIONS 
The present study deals with formulation and evaluation of 
solid lipid microparticles in the size range suitable for oral 
delivery by solvent evaporation technique melt dispersion 
technique and w/o/w emulsion solvent evaporation 
techniques using organic solvents. A W/O/W emulsion 
solvent evaporation technique was finally considered best 
method to prepare the SLM since it generated microspheres 
with spherical shape. The encapsulation efficiency of the 
drug into glyceryl monostearate microparticles was 
substantially influenced by the preparation method and the 
physical state of the drug to be incorporated. The w/o/w 
emulsion solvent evaporation techniques and the 
incorporation of the drug as an aqueous solution gave the 
best results with actual drug loadings up to 16% and an 
encapsulation efficiency of approximately 72%. The in-vitro 
release study of diltiazem hydrochloride was carried out for 
24 which resulted in initial burst release of 17 % followed 
by slow release of 84.51 %. The release data were fitted into 
equations for the zero-order, first-order, Higuchi release 
model and Krosmeyer Peppas model. The interpretation of 
data was based on the values of the resulting regression 
coefficients. The in-vitro drug release showed the regression 
coefficient values for Higuchi’s model (r2 = 0.9759) and 
Krosmeyer Peppas model (r2 = 0.986) and a value of n = 
0.576. In-vivo studies were carried out in albino rats as per 
the established protocol and the pharmacokinetic parameters 
were determined. Cmax value for SLM formulation was 
observed was 235.85±1.29 where Cmax value achieved in 
case of drug suspension was 218.59±1.47   Tmax value 
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remained for 8 h (i.e., between 4h to 12 h time interval) in 
the SLM formulation indicating sustained release of drug 
whereas in pure drug without polymer, the highest 
concentration (Cmax) was observed at first time point, i.e., 2 
h, this was considered as Tmax. Microparticles formulation 
stored at 4 ± 1°C showed the k value as 11.51 × 10-4, t10% 
value of nearly 94.45 days, t1/2 value was 602.61 days, while 
those stored at 25 ± 1oC showed the k value as × 10-4 and 
t10% value of nearly 45.1 days, t1/2 value of nearly 301.30 
days. 
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